BeiGene Ltd Stock News

CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.

The companies will leverage their combined technology and expertise in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of

(Bloomberg) -- I-Mab, a Chinese drug developer expanding in the U.S., is seeking a partner to jointly develop and sell a cancer drug in the world’s biggest economy, according to people familiar with

There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case for the sector.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) * Abbott Laboratories (NYSE: ABT) * Acceleron Phar

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatmen

Nuveen Asset Management LLC cut its position in Beigene Ltd (NASDAQ:BGNE) by 16.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Th

Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 1,500 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $160.00, for a total transaction

Akero Therapeutics (NASDAQ:AKRO) and Beigene (NASDAQ:BGNE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, insti

A phase 3 trial at BeiGene met its primary endpoint. Molina calls off deal. Alnylam gets its drug fast-tracked.

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on BeiGene (BGNE), with a price target of $184.00. The company's

Although it didn't disclose data for the study, the Beijing-based biotech company said it planned to seek Chinese approval for tislelizumab in first-line, non-squamous non-small-cell lung cancer. The

The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 13.) * Chembio Diagnostics Inc (NASDAQ: CEMI)

BeiGene (NASDAQ:BGNE) announces positive results from a Phase 3 clinical trial evaluating PD-1 inhibitor tislelizumab, combined with pemetrexed [Eli Lilly's (NYSE:LLY) Alimta] and platinum-based chemo

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatmen